Creating the Shift from Autologous to Allogeneic CAR T Therapy

CAR T and the Rise of Cellicon Valley

David D. Chang, M.D., Ph.D. CEO & Co-Founder Allogene Therapeutics May 2019



Disclosures

Executive/Board Member/Ownership Interest (Current and Previous)

- Allogene Therapeutics (President, Chief Executive Officer & Co-Founder)
- Kite Pharma (Former Executive Vice President of Research & Development/Chief Medical Officer)
- Kronos Bio (Scientific Advisory Board)
- A2 Biotherapeutics (Board Member)
- Peloton Biotherapeutics (Board Member)
- Vida Ventures (Venture Partner)

Forward-Looking Statements

To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this Presentation include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and initiating clinical trials, (ii) the success and timing of our collaboration partner's ongoing and planned clinical trials, (iii) our ability to obtain and maintain regulatory approval of any of our product candidates, (iv) our plans to research, discover and develop additional product candidates, including by leveraging next generation technologies and expanding into solid tumor indications, (v) our ability to establish manufacturing capabilities, and our and our collaboration partner's ability to manufacture our product candidates and scale production, and (vi) our ability to meet the milestones set forth herein. Various factors may cause differences between Allogene's expectations and actual results as discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the period ended March 31, 2019 filed with the SEC.

Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.



A Cancer Immunotherapy Journey to Engineered T-Cell Therapy

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Tisagenlecleucel in Children and Your Adults with B-Cell Lymphoblastic Leuke

S.L. Maude, T.W. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittence P. Bader, M.R. Verneris, H.E. Stefanski, G.D. Myers, M. Qayed, B. De Mo H. Hiramatsu, K. Schlis, K.L. Davis, P.L. Martin, E.R. Nemecek, G.A. Y C. Peters, A. Baruchel, N. Boissel, F. Mechinaud, A. Balduzzi, J. Krue C.H. June, B.L. Levine, P. Wood, T. Taran, M. Leung, K.T. Mueller, Y. Z K. Sen, D. Lebwohl, M.A. Pulsipher, and S.A. Grupp

08/30/2017 FDA approves Kymriah[®]

A Milestone for CAR T Cells

Eric Tran, Ph.D., Dan L. Longo, M.D., and Walter J. Urba, M.D., Ph.D.

More than 7 years have passed since the regres- toxic effects and complexity of this promising sion of advanced lymphoma was first reported therapy, it has been unclear whether the approach in a patient who had undergone the infusion of can be used to treat a large number of patients T cells engineered to express a chimeric antigen in clinical settings other than highly specialized receptor (CAR) targeting the CD19 antigen ex- academic centers.

pressed on the surface of both normal and malig- Two studies - a multicenter, phase nant B cells.1 Subsequent trials of CD19-targeted (ZUMA-1) by Neelapu et al.6 and a small CAR T-cell therapy showed a complete response series study by Schuster et al.7 - the rein some patients with relapsed or chemotherapy- which are now published in the Journal, refractory hematologic cancers for which there the efficacy of CD19-targeted CAR T-cell were no effective therapies.25

in patients with refractory lymphomas. In This personalized therapeutic approach entails studies, patients received autologous T co

the removal of peripheral-blood T cells from a were genetically engineered to express patient, followed by in vitro activation, genetic generation anti-CD19 CARs that were co modification, and expansion of the T cells under of an extracellular antigen-binding domain Good Manufacturing Practice conditions, and from the single-chain variable fragmen finally the infusion of the cells back into the CD19-specific antibody FMC63, along w patient (Fig. 1A). Because of the challenging intracellular T-cell signaling domains, one

> N ENGLJ MED 377;26 NEJM.ORG DECEMBER 28, 2017 The New England Journal of Medicine

10/18/2017 FDA approves Yescarta[®]

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma


S.S. Neelapu, F.L. Locke, N.L. Bartlett, L.J. Lekakis, D.B. Miklos, C.A. Jacobson, I. Braunschweig, O.O. Oluwole, T. Siddigi, Y. Lin, J.M. Timmerman, P.J. Stiff, J.W. Friedberg, I.W. Flinn, A. Goy, B.T. Hill, M.R. Smith, A. Deol, U. Farooq, P. McSweeney, J. Munoz, I. Avivi, J.E. Castro, J.R. Westin, J.C. Chavez, A. Ghobadi, K.V. Komanduri, R. Levy, E.D. Jacobsen, T.E. Witzig, P. Reagan, A. Bot, J. Rossi, L. Navale, Y. Jiang, J. Aycock, M. Elias, D. Chang, J. Wiezorek, and W.Y. Go



Autlogous CD19 CAR T Therapy in Relapsed and Refractory DLBCL

62-year-old man with refractory DLBCL Prior Therapies

- R-CHOP
- R-GDP
- R-ICE
- R-Revlimid




Baseline

Day 90




Engineered Cell Therapy: From Bench to Bedside






Autologous CAR T: Learning from the First Revolution



Allogeneic CAR T Therapy: The Next Potential Breakthrough




Allogene: Leading the Future of AlloCAR T[™] Cell Therapy

UNIQUE EXPERIENCE

Deep understanding of CAR T manufacturing needs and notable success piloting a CAR T to approval

STRONG FOUNDATION

Strong balance sheet, expansive portfolio and knowledgeable team across all key functions



FOCUSED ALLOGENEIC PLATFORM


Technology platform focused 100% on bringing AlloCAR T therapy to patients

PATH TO APPROVAL

Experience in designing CAR T studies to potentially accelerate AlloCAR T[™] development




UCART19: The First AlloCAR T[™] in Clinical Development






Controlling Graft-vs-Host Disease (GvHD) Reaction




- GvHD: a potentially serious complication where allogeneic cells ("the graft") attack the patient's healthy cells ("the host")
- Risk of GvHD can be reduced by inactivating T cell receptors (TCR)
- Mild cases of Grade 1 acute GvHD reactions limited to skin observed with UCART19 in ongoing clinical studies (ASH 2018)



Creating a Window of Persistence



Anti-CD52 mAb (ALLO-647) intended to reduce the likelihood of the patient's immune system from rejecting AlloCAR T[™] cells



BCMA CAR T cells knocked out for CD52 are resistant to ALLO-647 in a complement-dependent cytotoxicity assay



UCART19 PALL & CALM Studies Targeting CD19 R/R ALL




UCART19 ALL Pediatric (PALL) and Adults (CALM) Study Overview Servier Sponsored

Eligible patients with CD19+ B-ALL and:

- Morphological or MRD+
- Failed previous treatment options
- Objectives:
 - Primary: Safety and tolerability
 - Secondary: Anti-leukemic activity
 - Exploratory: UCART19 expansion and persistence
- PALL ongoing:
 - ✓ n= 7 treated with 2 x 10^7 total cells
- CALM dose escalation ongoing:
 - ✓ n= 6 treated at DL1 (6 x 10^6 total cells)
 - ✓ n= 6 treated at DL2 (6 to 8 x 10^7 total cells)
 - \rightarrow DL3 (1.8 to 2.4 x 10⁸ total cells) ongoing

PALL/CALM ASH 2018



- Fludarabine: 90 mg/m² for adults; 150 mg/m² for pediatrics
- Cyclophosphamide: 1500 mg/m² for adults; 120mg/kg for pediatrics
- Anti-CD52 mAb: 1 mg/kg both adults and pediatrics



UCART19: Manageable AE Profile in Phase 1 Studies



N=21	G1	G2	G 3	G4	G5	All grades		
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)		
AEs related to UCART19								
Cytokine release syndrome	4 (19.0)	12 (57.1)	2 (9.5)	1* (4.8)	-	19 (90.5)		
Neurotoxicity events	7 (33.3)	1 (4.8)	-	-	-	8 (38.1)		
Acute skin graft-versus-host disease **	2 (9.5)	-	-	-	-	2 (9.5)		
AEs related to lymphodepletion and/or UCART19								
Viral infections †	1 (4.8)	2 (9.5)	4 (19.0)	1 (4.8)	-	8 (38.1)		
Prolonged cytopenia***	-	-	-	6 ‡ (28.5)	-	6 (28.5)		
Neutropenic sepsis				1 (4.8)	1* (4.8)	2 (9.5)		
Febrile neutropenia/ septic shock					1 (4.8)	1 (4.8)		
Pulmonary hemorrhage					1‡ (4.8)	1 (4.8)		

ASH 2018

14


n: number of patients with at least one AE by worst grade

* 1 DLT at DL1 related to UCART19: G4 CRS associated with G5 neutropenic sepsis (death at D15 post-infusion)

** GvHD confirmed by biopsy in 1 out of 2 cases

*** Persistent Grade 4 neutropenia and/or thombocytopenia beyond Day 42 post UCART19 infusion, except if >5% bone marrow blasts

[‡] 1 DLT at DL2 related both to UCART19 and LD: G4 prolonged cytopenia associated with infection and pulmonary hemorrhage (death at D82 posterior using








Trial	Patients Enrolled & Treated	CR/CRi with FCA	CR/CRi with FC only	CR/CRi Overall	
PALL	7	100% (6/6)	0% (0/1)	86% (6/7)	
CALM	14	73% (8/11)	0% (0/3)	57% (8/14)	
Pooled	21	82% (14/17)	0% (0/4)	67% (14/21)	

ASH 2018 ; FCA: Fludarabine, cyclophosphamide & alemtuzumab (anti-CD52 mAb); FC: Fludarabine & cyclophosphamide

- UCART19 expansion observed in 15/17 patients with FCA and 0/4 patients with FC only
- Allogene will use its Proprietary anti-CD52 mAb (ALLO-647) for AlloCAR T[™] Programs




Anti-CD52 Antibody May Lead to Deeper Immune Suppression





AlloCAR T[™] Cells Will Be Available On Demand





Current Manufacturing Capabilities & Planned Expansion

Current South San Francisco Facility

- Manufacturing process development & optimization
- Analytic methods for in-process characterization & improvement
- Quality Assurance and Quality Control support

Planned East Bay Area Facility (Newark, CA)

- 118,000 sq./ft facility planned
- In-house manufacturing capability build underway:
 - GMP manufacturing for clinical supply
 - Potential commercial launch upon approval

Current CMO Support

- Dedicated purpose built GMP suite
- Clinical supply manufacturing, formulation & release





Deep AlloCAR T[™] Pipeline Targeting Vast Array of Tumor Types

CATEGORY	PROGRAM	PRE-CLINICAL	PHASE 1	PHASE 2/3 ¹
Hematological Malignancies	UCART19 (CD19/ALL) ² (Servier Sponsored)			
	ALLO-501 (CD19/NHL) ²			
	ALLO-715 (BCMA/MM)			
	ALLO-819 (FLT3/AML)			
	CD70 (Hematological Malignancies)			
Solid Tumors	CD70 (RCC)			
	DLL3 (SCLC)			
Lymphodepletion Agent	ALLO-647 (Anti-CD52 mAb) ³			

¹ Phase 3 may not be required if Phase 2 is registrational

² Servier holds ex-US commercial rights


³ ALLO-647 intended to enable expansion and persistence of allogeneic CAR T product candidates



ALLO-501 ALPHA Study Targeting CD19 in R/R NHL

ALLO-501 and ALLO-647 Phase 1 Study Overview (Allogene-Sponsored)

- Initiated 1H 2019
- Eligible patients with relapsed/refractory large Bcell lymphoma or follicular lymphoma and:
 - Failed at least two prior lines of therapy
 - No prior anti-CD19 therapy
 - Absence of pre-existing donor (product)-specific anti-HLA antibodies
- Objectives:
 - Primary: Safety, tolerability and recommended P2 doses for ALLO-501 and ALLO-647
 - Secondary: Anti-tumor activity, ALLO-501 cellular kinetics, ALLO-647 PK, immunogenicity and host lymphocyte reconstitution
- Dose-escalation of ALLO-501: 40 to 360 x 10⁶ CAR+ cells in 3+3 design
- Up to 24 patients



13 mg/d x 3 days

Treatment:

• Starting cell dose: 40 X 10⁶ CAR+ cells


Lymphodepletion:


- ALLO-647:
- Fludarabine: 30 mg/m²/d x 3 days
- Cyclophosphamide: 300 mg/m²/d x 3 days



Servier holds ex-US rights to ALLO-501

ALLO-715: BCMA AlloCAR T[™] for Multiple Myeloma (MM)





ALLO-715 showed activity *in vitro* against myeloma cell lines and *in vivo* in xenograft models


- IND Submitted 1H 2019
- Phase 1 clinical trial initiation expected in 2019
 - Open label, multi-center, dose escalation study in r/r MM
- Pre-clinical study published in *Molecular Therapy* validates the potential for an AlloCAR T to treat MM




ALLO-819: FLT3 CAR T for Acute Myeloid Leukemia (AML)


AML is a high unmet medical need with limited treatment options

- Cancer of hematopoietic progenitor cells most common in adults
- Lower survival rate of all hematological malignancies (5-year OS < 28%)
- Majority of patients relapse, novel therapies are urgently needed





ALLO-819 Depletes Primary AML Blasts Ex Vivo



Five Allogenee

CD70 for Renal Cell Carcinoma (RCC)

CD70 is the ligand for the co-stimulatory receptor CD27

 Normal CD70 expression is limited to activated lymphocytes and APCs

CD70 expression¹:

- RCC tumor samples (80-100%)
- AML (96%)
- DLBCL (71%), MM (63%), CLL (50%),
- GBM (35%)

Lead CARs chosen from several Abs targeting different regions of the protein


 Candidates screened to show long-lived activity in low-expressing cell lines similar to disease level expression

Pre-clinical data presented at AACR 2019; candidate to be selected for IND-enabling studies



CD70 Expression High in RCC and Low in Normal Tissues







Engineering a Future for AlloCAR T[™] in Solid Tumors

